Published in Nucl Med Commun on January 01, 1998
The interpretation of lung scans. Nucl Med Commun (1998) 0.75
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol (2005) 2.65
Comparison of technetium-99m-HM-PAO leukocytes with indium-111-oxine leukocytes for localizing intraabdominal sepsis. J Nucl Med (1990) 2.63
Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med (1996) 2.03
Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. Eur J Nucl Med (1999) 1.95
PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med (1997) 1.83
A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med (1999) 1.67
99Tcm sestamibi--a new agent for parathyroid imaging. Nucl Med Commun (1989) 1.63
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2000) 1.62
Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging (2003) 1.59
Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. Eur Respir J (1991) 1.54
The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma. Eur J Surg Oncol (2006) 1.51
Focal abnormalities detected by 18FDG PET in epileptic encephalopathies. Arch Dis Child (1996) 1.48
18F-FDG PET-CT uptake is a feature of both normal diameter and aneurysmal aortic wall and is not related to aneurysm size. Eur J Nucl Med Mol Imaging (2014) 1.47
Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood (1998) 1.44
Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer (2012) 1.41
Gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant (1994) 1.40
Secretion of [123I] iodide in breast milk following administration of [123I] meta-iodobenzylguanidine. Eur J Nucl Med (1994) 1.39
Is perfusion lung scanning hazardous in pulmonary hypertension? Nucl Med Commun (1995) 1.38
Cerebral perfusion deficits in divers with neurological decompression illness. Nucl Med Commun (1993) 1.38
18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma (2000) 1.34
Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med (1992) 1.28
Direct access MRI for general practitioners--influence on patient management. Clin Radiol (1998) 1.26
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg (1999) 1.24
Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer (2000) 1.16
Radionuclide parathyroid imaging. J Nucl Med (1997) 1.15
Dual energy X-ray absorptiometry normal reference range use within the UK and the effect of different normal ranges on the assessment of bone density. Br J Radiol (1995) 1.13
Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br (1998) 1.12
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol (2010) 1.08
Letter to the editor re: positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol (2013) 1.07
Radiation dose rates post 131I therapy and advice to patients on discharge from hospital. Health Phys (1997) 1.07
Radiation dose rates from patients undergoing PET: implications for technologists and waiting areas. Eur J Nucl Med (2000) 1.07
Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation. Am Rev Respir Dis (1993) 1.06
(99m)Tc(V)DMSA quantitatively predicts (188)Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med (2000) 1.06
18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol (2000) 1.02
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging (2002) 1.00
Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers. Thorax (1991) 0.99
The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging (2004) 0.99
A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Neurology (1997) 0.98
Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med (1996) 0.97
Regional lung epithelial leakiness in smokers and nonsmokers. Nucl Med Commun (1985) 0.96
The size of normal adrenal glands on computed tomography. Clin Radiol (1994) 0.95
Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet (1984) 0.94
Computed tomography of diffuse, non-metastatic enlargement of the adrenal glands in patients with malignant disease. Clin Radiol (1994) 0.93
Pulmonary deposition of a nebulised aerosol during mechanical ventilation. Thorax (1993) 0.92
Variability in the measurement of nebulized aerosol deposition in man. Clin Sci (Lond) (1991) 0.92
Recurrent Strongyloides stercoralis infection in a patient with T-cell lymphoma-leukaemia. Lancet (1984) 0.92
Non-invasive management of fever and breathlessness in HIV positive patients. Eur Respir J (1991) 0.91
Lung 99Tcm-DTPA transfer: a method for background correction. Nucl Med Commun (1985) 0.91
[(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg (2000) 0.91
Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med (2001) 0.90
Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med (2000) 0.90
Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med (2000) 0.89
The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol (2000) 0.89
FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med (2001) 0.88
2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol (2000) 0.88
Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg (1999) 0.87
Positron emission tomography in imaging spinal cord tumors. J Child Neurol (2000) 0.87
18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol (Oxf) (2006) 0.87
Ventilation perfusion imaging--again. Nucl Med Commun (1992) 0.86
Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma. Eur J Nucl Med (1998) 0.86
Parathyroid imaging: preoperative localization. Nucl Med Commun (2003) 0.85
Solid phase synthesis of [18F]labelled peptides for positron emission tomography. Bioorg Med Chem Lett (2000) 0.85
Folic acid absorption in patients infected with the human immunodeficiency virus. J Intern Med (1991) 0.85
The challenges of integrating molecular imaging into the optimization of cancer therapy. Integr Biol (Camb) (2011) 0.85
Positron emission tomography in the management of lymphomas. Clin Oncol (R Coll Radiol) (2002) 0.85
Effect of a spacer on pulmonary aerosol deposition from a jet nebuliser during mechanical ventilation. Thorax (1995) 0.84
Exposure of critical groups to nuclear medicine patients. Appl Radiat Isot (1999) 0.83
Pentavalent 99Tcm-DMSA imaging in patients with bone metastases. Nucl Med Commun (1997) 0.83
Ulcerative colitis developing after amoebic dysentery in a haemophiliac patient with AIDS. Gut (1992) 0.83
Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl Med Commun (2003) 0.83
Diabetes and bone: advantages and limitations of radiological, radionuclide and hybrid techniques in the assessment of diabetic foot. Minerva Endocrinol (2009) 0.82
Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine (1996) 0.82
Therapeutic aerosols in children. BMJ (1993) 0.82
Use of imaging in the management of malignant pleural mesothelioma. Clin Radiol (2005) 0.82
Scale-up of a cyclone bioreactor. J Chem Technol Biotechnol (1994) 0.81
Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med (1998) 0.81
Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy. Clin Immunol (2009) 0.81
The role of positron emission tomography in the management of colorectal cancer. Colorectal Dis (2004) 0.80
In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. Eur J Nucl Med (2001) 0.80
Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis. Nucl Med Commun (1993) 0.80
Pulmonary permeability in hematologic malignancies. Effects of the disease and cytotoxic agents. Cancer (1986) 0.79
Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Eur Respir J (1997) 0.79
Iodine-123 salmon calcitonin, an imaging agent for calcitonin receptors: synthesis, biodistribution, metabolism and dosimetry in humans. Eur J Nucl Med (1998) 0.79
Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med (1994) 0.79